



Resource impact summary report

Resource impact

Published: 9 January 2025

www.nice.org.uk

Contents

Resource impact summary report	3
Eligible population for tebentafusp	3
Financial resource impact (cash items)	4
Capacity impact	4
Key information.....	4
About this resource impact summary report.....	5

Resource impact summary report

This summary report is based on the NICE assumptions used in the [resource impact template](#). Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.

NICE has recommended tebentafusp as an option for treating HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company provides it according to the commercial arrangement.

Eligible population for tebentafusp

Table 1 shows the population who are eligible for tebentafusp and the number of people who are expected to have tebentafusp in each of the next 5 years.

Table 1 Population expected to be eligible for and have tebentafusp in England

Eligible population and uptake	Current practice	2025-26	2026-27	2027-28	2028-29	2029-30
People eligible for tebentafusp (rounded to nearest 5)	120	120	120	120	125	125
Uptake for tebentafusp (%)	0	25	50	50	50	50
People having tebentafusp each year (rounded to nearest 5)	0	30	60	60	60	60

The market share for tebentafusp is based on projections from the manufacturer and NHS England.

Treatment options for the eligible population

The other treatment for the eligible population is pembrolizumab.

Both tebentafusp and pembrolizumab are administered intravenously, but tebentafusp has more administrations. In addition, the first 3 administrations of tebentafusp require admission to hospital and 16 hours of monitoring.

For more information about the treatments, such as dose and average treatment duration, see the [resource impact template](#).

Financial resource impact (cash items)

The company has a [commercial arrangement](#). This makes tebentafusp available to the NHS with a discount.

Users can input the confidential price of tebentafusp and amend other variables in the [resource impact template](#).

The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.

For further analysis or to calculate the financial impact of cash items, see the [resource impact template](#).

Capacity impact

Table 2 shows the impact on capacity activity in each of the next 5 years.

Table 2 Capacity impact (activity) in England

Capacity impact	Current practice	2025-26	2026-27	2027-28	2028-29	2029-30
Number of administration appointments	950	1,680	2,430	2,450	2,470	2,500
Number of tests (rounded to nearest 5)	0	320	320	325	330	330

For further analysis or to calculate the financial capacity impact from a commissioner (national) and provider (local) perspective, see the [resource impact template](#).

Key information

Table 3 Key information

Time from publication to routine commissioning funding	90 Days
--	---------

Programme budgeting category	02E cancer, skin
Commissioner	NHS England
Provider	NHS hospital trusts
Pathway position	First line

About this resource impact summary report

This resource impact summary report accompanies the [NICE guidance on Tebentafusp for treating advanced \(unresectable or metastatic\) uveal melanoma](#) and should be read with it.

ISBN: 978-1-4731-6774-2